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Abstract
Background: The tumour supressor gene TP53 is thought to be involved in neural apoptosis. The
polymorphism at codon 72 in TP53 and the long form variants of the upstream variable number of tandem
repeats (uVNTR) polymorphism in the dopamine D4 receptor (DRD4) gene are reported to confer
susceptibility to schizophrenia.
Methods: We recruited 934 patients with schizophrenia and 433 healthy individuals, and genotyped the
locus of the TP53 codon 72 and DRD4 uVNTR polymorphisms by combining the polymerase chain
reaction-restriction fragment length polymorphism method (PCR-RFLP) with direct sequencing.
Results: No significant differences were found in the frequency of the genotype of the TP53 codon72
polymorphism between patients with schizophrenia and their controls. However, the long form alleles (≥
5 repeats) of the DRD4 uVNTR polymorphism were more frequent in patients with schizophrenia than in
controls (p = 0.001). Hence, this class of alleles might be a risk factor for enhanced vulnerability to
schizophrenia (odds ratio = 3.189, 95% confidence interval = 1.535-6.622). In the logistic regression
analysis, the long form variants of the DRD4 polymorphism did predict schizophrenia after the
contributions of the age and gender of the subjects were included (p = 0.036, OR = 2.319), but the CC
and GG genotypes of the codon 72 polymorphism of TP53 did not.
Conclusions: The long form variants of the uVNTR polymorphism in DRD4 were associated with
schizophrenia, in a manner that was independent of the TP53 codon 72 polymorphism. In addition, given
that the genetic effect of the TP53 codon 72 polymorphism on the risk of developing schizophrenia was
very small, this polymorphism is unlikely to be associated with schizophrenia. The roles that other single
nucleotide polymorphisms (SNPs) in the TP53 gene or in other apoptosis-related genes play in the synaptic
dysfunction involved in the pathogenesis of schizophrenia should be investigated.
Published: 29 December 2009
BMC Medical Genetics 2009, 10:147 doi:10.1186/1471-2350-10-147
Received: 18 February 2009
Accepted: 29 December 2009
This article is available from: http://www.biomedcentral.com/1471-2350/10/147
© 2009 Lung et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2009, 10:147 http://www.biomedcentral.com/1471-2350/10/147
Page 2 of 8
(page number not for citation purposes)
Background
The results of neuropsychological and neuroimaging
studies suggest that abnormal connections between vari-
ous cortical and subcortical regions of the brain play an
important role in the pathogenesis of schizophrenia [1,2].
During the last two decades, remarkable progress has been
made in identifying changes in the brain that are related
to the pathophysiology of schizophrenia. Although the
aetiology remains unknown, several convergent findings
suggest that disruption of the cortical synaptic circuitry is
a central defect in schizophrenia; these include the pro-
gressive loss of cortical gray matter during the first episode
of psychosis, reduced synaptic markers, reduced neuropil,
and reductions in neurons that are specific to cortical lay-
ers [3]. The underlying mechanisms that lead to synaptic
dysfunction in patients with schizophrenia remain
unknown; however, dysregulation of neuronal apoptosis
has been suggested to contribute to the pathophysiology
of the disease [4,5]. The pro-apoptotic events that occur
within the brains of patients with schizophrenia do not
affect the number of cortical neurons in the prefrontal cor-
tex [6,7], but do give rise to a reduction of neuropil that is
accompanied by a high neuronal density [8].
Among the proteins that are related to apoptosis, the level
of Bcl-2 is reduced by 25% in the middle temporal gyrus
in patients with schizophrenia as compared with controls.
A high Bax/Bcl-2 ratio is also detected in the neurons and
glia of the temporal cortex of patients with schizophrenia
[9], which suggests that pro-apoptotic stimuli might be
more likely to lead to the uncontrolled release of cyto-
chrome c in these cells than in normal cells. The excess
cytochrome c is released into the cytosol where it initiates
the caspase cascade [10,11]. The well-known tumour sup-
pressor p53, which is encoded by the TP53 gene, has been
proposed to be an upstream regulator of the intrinsic
apoptotic pathway, which is mediated by Bax [12]. In gen-
eral, in response to DNA damage, p53 triggers either
growth arrest through the cell cycle regulator p21 and/or
apoptosis via PUMA-Bax signalling [13]. Moreover, it has
been shown that increased TP53 expression in the mouse
embryonic brain results in neuronal damage [14]. It has
also been observed that the TP53 gene acts to control the
elimination of cells with genetic abnormalities; for exam-
ple, p53-mediated neuronal apoptosis is induced in
patients with schizophrenia [15,16]. Therefore, it was of
interest to determine whether the TP53 gene confers vul-
nerability to schizophrenia. The TP53 codon 72 polymor-
phism, an arginine (Arg; CGC)/proline (Pro; CCC)
substitution polymorphism at codon 72 of TP53, is spec-
ulated to affect the induction of apoptosis by p53. The two
genetic variants have been reported to function differ-
ently: the Arg72 variant is considered to trigger apoptosis
more efficiently than the Pro72 variant. Moreover, the
Arg72 variant is localised to mitochondria and induces
the release of excess cytochrome c into the cytosol [17].
This polymorphism is also reported to be associated with
vulnerability to cancer: the Pro/Pro genotype is a risk fac-
tor associated with enhanced vulnerability to epithelial
cancers, such as lung cancer (odds ratio (OR) = 2.98) [18],
colorectal cancer (OR = 1.699) [19], transitional cell car-
cinoma [20], and cervical cancer [21]. However, it
remains unclear whether this polymorphism is associated
with schizophrenia.
The D4 dopamine receptor (DRD4) gene contains an
upstream variable number of tandem repeats (uVNTR)
polymorphism that comprises between two and 10
repeats. The polymorphism is located in exon 3 of the
gene, which encodes the cytoplasmic portion of the recep-
tor and is critical for its biological function [22,23].
According to experimental evidence from functional stud-
ies, the two-repeat and four-repeat variants are associated
with a greater reduction in cyclic adenyl monophosphate
(cAMP) levels upon binding to dopamine than the seven-
repeat variant [9,24]. This polymorphism has been linked
to variations in dopaminergic signalling and confers sus-
ceptibility to schizophrenia, especially the long form var-
iants [22,25]. Abnormalities in dopaminergic signalling
are usually observed in patients with schizophrenia [26].
Porat et al. have suggested that higher concentrations of
dopamine can induce apoptosis and increase the expres-
sion of TP53 [27]. Therefore, the TP53 gene might be
linked to the dopaminergic signalling pathway, even
though it is not yet known whether p53 interacts with
DRD4. In the study reported herein, our aim was to inves-
tigate the role of the TP53 codon 72 polymorphism in
schizophrenia. In addition, we investigated the possible




For this study, 934 patients with schizophrenia (643
males, average age of 36.69 years, standard deviation (SD)
= 12.20) were recruited in Southern Taiwan from outpa-
tient services, the intensive care unit, the community psy-
chiatric clinic, psychiatry referrals, and the acute wards of
a teaching hospital. All patients were diagnosed by senior
psychiatrists in a teaching hospital according to the crite-
ria of the Diagnostic Statistical Manual, Fourth Edition
[28], and were receiving antipsychotic medication when
the blood samples were taken. Each patient was assessed
independently by at least two psychiatrists on the basis of
case records and interviews. The interviews were adminis-
tered by trained and reliable assessors and the diagnosis
depended on the consensus of two assessors. Written
informed consent was obtained from all participants and
the study protocol was approved by the Institutional
Review Board of Kaohsiung Armed Forces General Hospi-
tal.BMC Medical Genetics 2009, 10:147 http://www.biomedcentral.com/1471-2350/10/147
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DNA extraction
DNA was extracted from the blood samples by using a
DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany)
according to the instructions of the manufacturer. The
extracted DNA was diluted to a final concentration of 100
ng/μl and stored at -80°C until further use.
Genotyping of the TP53 codon 72 polymorphism
The Pro72Arg polymorphism of TP53 was analysed by the
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) method. The PCR was per-
formed using the hot-start technique in a final reaction
volume of 25 μl with 1.5 mM MgCl2. The primers for PCR
amplification were: forward 5'-CAA CGT TCT GGT AAG
GAC AA-3'; reverse 5'-GCC TAA GGG TGA AGA GGA A-3'.
The following reaction conditions were used: 35 cycles of
30 s at 94°C (denaturation), 30 s at 55°C (annealing),
and 30 s at 72°C (extension). The PCR products were
digested with BstUI at 60°C for 2 h, and were then visual-
ised on a 2% agarose gel that contained 0.5 μg/ml ethid-
ium bromide. The original undigested PCR product was
488 bp in length. PCR products that corresponded to the
Arg72 (CGC) variant were digested into fragments of 222
and 266 bp by BstUI, whereas the Pro72 (CCC)-specific
product remained undigested. The genotypes were
recorded by at least two well-trained assessors who were
blinded to the clinical characteristics of the study sample.
DNA sequencing
The results of the PCR-RFLP analysis were confirmed by
direct sequencing. Briefly, the PCR product was purified
using a QIAquick purification column (Qiagen, Valencia,
USA) and then used as the template for cycle sequencing
with the BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, USA), according to the
instructions of the manufacturer. The extended products
were separated on an ABI PRISM™ 3130 Genetic Analyzer
(Applied Biosystems, Foster City, USA) after alcohol pre-
cipitation.
Statistical analysis
The variables were analysed using SPSS for Windows ver-
sion 15.0 (SPSS, Chicago, IL, USA). Continuous variables
were shown as means ± SD and categorical variables were
presented as proportions. An unpaired t test was used to
compare continuous variables between groups, and Pear-
son's chi-square (χ2) test was applied to the categorical
variables. χ2 tests were used to test whether the genotype
frequencies at each locus conformed to Hardy-Weinberg
equilibrium. In addition, a χ2 test was used to determine
whether intergroup differences in the genotype distribu-
tions and allele frequencies of the TP53 codon 72 and
DRD4 uVNTR polymorphisms were significant between
cases and controls. Moreover, a hierarchical logistic
regression analysis with dummy variables was used to
evaluate whether the TP53 and DRD4 polymorphisms
were independent factors associated with vulnerability to
schizophrenia. Possible interaction between the polymor-
phisms was also analysed in the logistic regression. A total
of three dummy variables were created: p53CC, p53GG,
and DRD4c. For the variable p53CC, a score of 1 referred
to the CC genotype of the TP53 codon 72 polymorphism,
whereas 0 referred to the other possible genotypes. For
p53GG, a score of 1 referred to the GG genotype of the
TP53 codon72 polymorphism and 0 referred to the other
possible genotypes. For DRD4c, 1 referred to the long
form allelic variants of the DRD4 uVNTR polymorphism
(≥ 5 repeats) and 0 referred to the short form allelic vari-
ants (≤ 4 repeats). The interrelationships among age and
gender of the subjects, genotype CC of the TP53 codon 72
polymorphism, long form variants (≥ 5 repeats) of the
DRD4 uVNTR polymorphism, and schizophrenia were
analysed by structure equation modelling with AMOS ver-
sion 7.0 (SPSS). The structural equation modelling tech-
niques used all the information that was provided by the
regression techniques and path analysis. If the p value was
greater than 0.05 and the adjusted goodness-of-fit index
was greater than 0.9, the null model corresponded to the
real structure.
Results
In this study, the subjects comprised 934 patients with
schizophrenia (643 males, average age of 36.69 years, SD
= 12.20) and 433 controls from the community (190
males, average age of 45.33 years, SD = 13.91). The distri-
butions of genotypes and alleles for the TP53 codon 72
and DRD4 uVNTR polymorphisms are shown in Table 1.
The genotype distribution of the TP53 codon 72 polymor-
phism conformed to the Hardy-Weinberg equilibrium in
both cases and controls (case: HWE-p = 0.884; control:
HWE-p = 0.084; Table 1). No significant differences were
found for the genotype distribution or allele frequencies
of the TP53 codon 72 polymorphism between the cases
and the controls (genotype: p = 0.229; allele: p = 0.404).
By contrast, the genotype distributions of the DRD4
uVNTR polymorphism did show significant differences
between the two groups. In our study cohort, the three
most common genotypes of the uVNTR in DRD4 were 4/
4, 2/4, and 2/2, and the distribution of these genotypes
was significantly different between the cases and the con-
trols (case: 4/4 = 57.00%, 4/2 = 28.77%, 2/2 = 6.56%;
control: 4/4 = 66.19%, 4/2 = 18.44%, 2/2 = 11.58%; P <
0.001). All DRD4 uVNTR alleles detected were categorised
into the following two groups: short form alleles (≤ 4
repeats) and long form alleles (≥ 5 repeats). In general,
alleles that contained more than six repeats were found
rarely in our population. Patients with schizophrenia
were significantly more likely to carry long form alleles (p
= 0.001), and these alleles were associated with a 3.189-
fold higher risk of schizophrenia that the short-form alle-BMC Medical Genetics 2009, 10:147 http://www.biomedcentral.com/1471-2350/10/147
Page 4 of 8
(page number not for citation purposes)
les (OR = 3.189, 95% CI = 1.535 - 6.622). The results of
the logistic regression analysis showed that age and gen-
der were associated with schizophrenia to a significant
level (p < 0.001, data not shown); therefore, the subse-
quent analyses of the genetic effect that was contributed
by the two polymorphisms were stratified by age and gen-
der of the subjects. The two dummy variables p53CC and
p53GG showed no significant association with schizo-
phrenia after the contributions of age and gender had
been taken into account (Model 1 in Table 2; p53CC: p =
0.203; p53GG: p = 0.571). However, the dummy variable
DRD4c was associated significantly with schizophrenia
(Model 2 in Table 2, p = 0.036, OR = 2.319), which indi-
cated that the long form variants (≥ 5 repeats) confer vul-
nerability to schizophrenia in our population. In
addition, no interaction between the dummy variable
DRD4c and p53CC was found (Model 3 in Table 2, p =
0.166). This result might suggest that the long form vari-
ants of the uVNTR polymorphism in DRD4 increase the
risk of developing schizophrenia in a manner that is inde-
pendent of the TP53 codon 72 polymorphism. To investi-
gate the possible interaction between the two
polymorphisms further, structure equation modelling
was used to clarify the inter-relationships between the age
and gender of the subject, the dummy variables p53CC
and DRD4c, and schizophrenia. The structural model
shown in Figure 1 demonstrates that the age and gender
of the subjects showed a stronger correlation with schizo-
phrenia than the genetic effect of the two polymorphisms.
Age, which showed a negative association with schizo-
phrenia, had the highest correlation coefficient (-0.26),
followed by gender (-0.184), DRD4c (0.061), and p53CC
(0.020). These results indicated that increasing age and
female gender correlate negatively with schizophrenia,
which is consistent with the observed higher incidence of
schizophrenia among young male individuals. The long
form variants (≥ 5 repeats) of the DRD4 uVNTR polymor-
phism showed a stronger positive correlation with schizo-
phrenia than the CC genotype of the TP53 codon 72
polymorphism. However, both of these genotypes did not
parallel to age and gender, which still not reach a signifi-
cant degree. According to the results of the analysis of
pathogenesis, which were consistent with the results of
the logistic regression, there was no interaction between
p53CC and DRD4c. These findings provide additional
evidence that these two polymorphisms are associated
independently with schizophrenia. In addition, given that
the genetic effect of the TP53 codon 72 polymorphism is
very small, it is more likely that this polymorphism is not
correlated with schizophrenia.
Discussion
Schizophrenia is a complex trait with a strong genetic
background [29,30] whose detailed pathogenesis remains
unclear. Recently, several studies have described the epi-
phenomenon that the incidence of cancer is decreased in
patients with schizophrenia compared with that in the
general population [31]. In addition, several interesting
findings have been proposed to be linked to resistance to
tumours in patients with schizophrenia; these include the
detection of excess secretion of dopamine, enhanced
activity of natural killer cells, and accelerated apoptosis in
patients with schizophrenia, together with the unexpected
anti-mutagenic effects of antipsychotic drugs [18,31,32].
Table 1: The distributions of genotypes and alleles for the TP53 codon 72 and DRD4 uVNTR polymorphisms.
Polymorphism Genotype frequency (%) HWE-p p value Allele frequency (%) P value Odds ratio 
(95% CI)
rs8064946 C/C C/G G/G C (Pro72) G (Arg72)
Patient 
(n = 917)





74 (17.33) 228 (53.40) 125 (29.27) 0.084 376 (44.03) 478 (55.97)
DRD4 uVNTR 2/2 2/3 2/4 2/5 3/3 3/4 3/5 4/4 4/5 4/6 5/6 Short (≤ 4 
repeats)




60 0 263 8 1 16 1 521 24 19 1 < 0.001 1774 
(97.05)




49 1 78 3 1 6 0 280 2 3 0 838 (99.05) 8 (0.95)
Genotyping results for the TP53 codon 72 polymorphism were lacking for 17 patients with schizophrenia and six controls; genotyping information 
for the DRD4 uVNTR polymorphism was lacking for 20 patients with schizophrenia and 10 controls; HWE-p: p value of chi-square test for Hardy--
Weinberg Equilibrium; a: odds ratio of the C allele to the G allele of the codon 72 polymorphism in TP53in relation to schizophrenia; b: odds ratio of 
the long form variants (≥ 5 repeats) to the short form variants (≤ 4 repeats) shows the former confers enhanced risk of vulnerability to 
schizophrenia.BMC Medical Genetics 2009, 10:147 http://www.biomedcentral.com/1471-2350/10/147
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The p53 gene is also speculated to be involved in resist-
ance to the formation of tumours in individuals with
schizophrenia. The induction of apoptosis by p53 and its
effects on the cell cycle may account for the neurodevelop-
mental abnormalities that are associated with schizophre-
nia, as well as the resistance to tumours. Among the
known SNPs in TP53, the CAA Ins/Del and 16 bp Ins/Del
polymorphisms were found to be associated with schizo-
phrenia in a case-control study of residents in Toronto. In
addition, the CAA Ins/Del polymorphism was shown by
transmission disequilibrium test (TDT) analysis to be
transmitted unequally in a Portuguese family with schizo-
phrenia [33]. The SNP rs2078486-A allele and a CAC
three-marker haplotype CAC were detected more fre-
quently in Chinese patients with schizophrenia, which
suggested that TP53 plays a role in susceptibility to schiz-
ophrenia [34]. Previously, we have found that the CC
(Pro/Pro) genotype of the TP53 codon 72 polymorphism
can be detected at a higher frequency in Taiwanese
patients with cancer, in particular those with colorectal
cancer, than in controls [19,20]. This SNP has been
reported to show no association with schizophrenia, the
age of onset of schizophrenia [32], or deficits in the neu-
rocognitive profile [35]. However, the role of this poly-
morphism in Taiwanese patients with schizophrenia
remains unclear. In addition, little is known about the
possible interactions between the codon 72 polymor-
phism of TP53 and other SNPs that are related to schizo-
phrenia. The aim of the case-control study described
herein was to explore the genetic association between the
SNP in codon 72 of TP53, the uVNTR polymorphism in
DRD4, and schizophrenia in a Taiwanese population.
We found that the frequency of the Pro72 variant (the C
allele) of the TP53 polymorphism was higher in patients
with schizophrenia than in controls from the community
(45.75% versus 44.03%), which was consistent with the
results of a study by Chiu et al. (46.8% vs. 40.5%) [32].
However, these differences were not statistically signifi-
cant. There was no statistical difference with respect to
either genotype or allele frequency between patients and
controls after stratification by gender and age. Interest-
Table 2: Results of hierarchical logistic regression analysis aimed at determining whether the TP53 codon 72 and DRD4 uVNTR 
polymorphisms were associated with schizophrenia after the contributions of age and gender were taken into account.
Model 1.
Variables B S.E. Wald df Sig. Exp(B)
Gender --0.891 0.128 48.735 1 < 0.001** 0.410
Age --0.045 0.005 83.772 1 < 0.001** 0.956
P53CC 0.218 0.171 1.618 1 0.203 1.244
P53GG 0.083 0.146 0.320 1 0.571 1.086
Constant 3.760 0.276 185.052 1 < 0.001 42.954
Model 2.
Variables B S.E. Wald df Sig. Exp(B)
Gender --0.891 0.128 48.735 1 < 0.001** 0.410
Age --0.045 0.005 83.772 1 < 0.001** 0.956
DRD4c 0.841 0.401 4.393 1 0.036* 2.319
Constant 3.777 0.270 195.381 1 < 0.001 43.668
Model 3.
Variables B S.E. Wald df Sig. Exp(B)
Gender --0.891 0.128 48.735 1 < 0.001** 0.410
Age --0.045 0.005 83.772 1 < 0.001** 0.956
DRD4c by p53CC 1.459 1.054 1.916 1 0.166 4.302
Constant 3.819 0.270 200.781 1 < 0.001 45.573
B: coefficient of regression; S.E.: Standard Error; Wald: the index of regression effect; df: degrees of freedom; Sig: P value; Exp(B): odds ratio; 
p53CC: dummy variable where 1 refers to the CC genotype of the TP53 codon 72 polymorphism and 0 refers to the other possible genotypes; 
p53GG: dummy variable where 1 refers to the GG genotype of the TP53 codon 72 polymorphism and 0 refers to the other possible genotypes; 
DRD4c: dummy variable where 1 refers to the long form allelic variants of the DRD4 uVNTR polymorphism (≥ 5 repeats) and 0 refers to the short 
form allelic variants (≤ 4 repeats); DRD4c by p53CC: the genetic effect attributed to the possible interaction between the long form variants of the 
DRD4 uVNTR polymorphism and the CC genotype of the TP53 codon 72 polymorphism; ** indicates statistical significance (p < 0.001).BMC Medical Genetics 2009, 10:147 http://www.biomedcentral.com/1471-2350/10/147
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ingly, we have shown previously that the Pro72 variant is
more prevalent in patients with colorectal cancer (56.1%)
or transitional cell carcinoma (62.7%) [19,20]. Taken
together, these results suggest that the Pro72 variant is
associated with a higher risk of cancer, but not schizo-
phrenia, than the Arg 72 variant. In addition, this finding
was consistent with earlier results from two independent
case-control studies, which rejected a link between the
codon 72 polymorphism in TP53 and increased suscepti-
bility to schizophrenia [18,32]. The question remains as
to whether p53 controls neuronal apoptosis as well as
serving as a protective factor against cancer in patients
with schizophrenia. It is unlikely that a conclusive result
will be obtained The answer is likely to be inconclusive,
even though the TP53 gene is suspected to be involved in
synaptic dysfunction in schizophrenia [36]. Several lines
of evidence indicate that the apoptotic activity of p53
might be modulated by polymorphisms in TP53. In par-
ticular, the codon 72 polymorphism has been reported to
affect the ability of p53 to induce apoptosis. However,
although the Pro/Pro genotype has been found to be more
frequent in patients with cancer than in controls, it was
not significantly less prevalent in patients with schizo-
phrenia than in controls. Hence, our results provide addi-
tional evidence that p53 is unlikely to contribute to the
resistance to tumours that is observed in patients with
schizophrenia.
Schizophrenia is a multi-factorial genetic disease [29,30]
that is suggested to be caused by the synergistic effect of
different genetic variants [37]. Previously, we have
reported that the long form alleles of the uVNTR polymor-
phism in DRD4 might a risk factor for vulnerability to
schizophrenia [25]. Therefore, in the study reported
herein, we analysed the possible interaction between the
TP53 codon 72 and DRD4 uVNTR polymorphisms. In a
cell-based assay, high levels of dopamine can induce
apoptosis and increase the level of expression of TP53
[27]. In addition, excess secretion of dopamine and syn-
aptic dysfunction (which is probably the consequence of
pro-apoptotic activity in neurons) can be observed in
patients with schizophrenia. These findings raise the pos-
sibility that dopaminergic signalling regulates both neural
differentiation and apoptosis in a dose-dependent man-
ner, and that this activity is related to the function of p53.
It has also been suggested that p53 serves as a negative reg-
ulator of the dopamine-triggered apoptosis that occurs in
response to DNA damage under oxidative stress. How-
ever, using different statistical models, we did not find any
interaction between these two polymorphisms that was
associated with schizophrenia. Our results suggested that
long form variants of the DRD4 uVNTR polymorphism
and genotype CC of the TP53 codon72 polymorphism
might not have a synergistic effect on the risk of schizo-
phrenia. In addition, given that the genetic effect of the
CC genotype of the TP53 codon 72 polymorphism on
schizophrenia is small, this genotype is unlikely to be
associated with schizophrenia.
Our results should be viewed in the light of certain limita-
tions. Firstly, with respect to the SNPs in TP53, we only
explored the association between the codon 72 polymor-
phism of TP53 and schizophrenia, as well as its possible
interaction with long form variants of the uVNTR poly-
morphism of DRD4. We did not analyse other SNPs in
TP53 that have been reported elsewhere to be associated
with schizophrenia [33,34]. A relative few markers across
the p53 gene plausibly do not fully determine its role in
schizophrenia, of particular, its function involves in apop-
tosis induction. Secondly, this was a case-control study,
rather than a family-based study, and the data obtained
might be insufficient to clarify the association between the
gene and the disease. For example, we were not able to
obtain information about the rate of transmission or link-
age disequilibrium. Thirdly, given that no non-Asian sub-
jects were recruited for this study, ethnic heterogeneity can
only be identified through a meta-analysis. However, we
did not perform a meta-analysis to distinguish whether
the results obtained might be false negative findings due
to population stratification. Finally, schizophrenia is a
complex disorder and it needs to be studied by multifac-
eted approaches, not solely by the analysis of SNPs.
Structural equation modelling of inter-relationships among  variables with respect to schizophrenia Figure 1
Structural equation modelling of inter-relationships 
among variables with respect to schizophrenia. 
p53CC: dummy variable where 1 refers to the CC genotype 
of the TP53 codon 72 polymorphism and 0 refers to the 
other possible genotypes; DRD4c: dummy variable where 1 
refers to the long form allelic variants of the DRD4 uVNTR 
polymorphism (≥ 5 repeats) and 0 refers to the short form 
allelic variants (≤ 4 repeats); AGFI: adjusted goodness-of-fit 
index. The numbers are the coefficients of correlation 
between two variables.BMC Medical Genetics 2009, 10:147 http://www.biomedcentral.com/1471-2350/10/147
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Conclusions
The VNTR polymorphism in DRD4 has been reported pre-
viously to be involved in the pathogenesis of schizophre-
nia [19,22]. The Pro72Arg polymorphism in TP53 has
been associated with the metastasis of tumours in colorec-
tal cancer and transitional cell carcinoma [19,20], but not
with schizophrenia. In addition, the polymorphism is
associated with the grade of malignancy rather than onset
of the disease. In the present study, we found that the
uVNTR polymorphism in DRD4 was associated with vul-
nerability to schizophrenia, but the Pro72Arg polymor-
phism in TP53 was not. No interaction between the two
polymorphisms was found in the statistical model. There-
fore it is necessary to investigate whether other SNPs in
the TP53 gene or SNPs in other apoptosis-related genes
play a role in the synaptic dysfunction that is involved in
the pathogenesis of schizophrenia.
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